- Home
- LMFA vs KZIA Comparison
LMFA vs KZIA Comparison
Compare LMFA & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LMFA
- KZIA
- Stock Information
- Founded
- LMFA 2008
- KZIA 1994
- Country
- LMFA United States
- KZIA Australia
- Employees
- LMFA N/A
- KZIA N/A
- Industry
- LMFA Finance: Consumer Services
- KZIA Biotechnology: Pharmaceutical Preparations
- Sector
- LMFA Finance
- KZIA Health Care
- Exchange
- LMFA Nasdaq
- KZIA Nasdaq
- Market Cap
- LMFA 9.2M
- KZIA 7.8M
- IPO Year
- LMFA 2015
- KZIA 1999
- Fundamental
- Price
- LMFA $2.19
- KZIA $1.42
- Analyst Decision
- LMFA Hold
- KZIA Strong Buy
- Analyst Count
- LMFA 1
- KZIA 1
- Target Price
- LMFA N/A
- KZIA $20.00
- AVG Volume (30 Days)
- LMFA 91.6K
- KZIA 116.4K
- Earning Date
- LMFA 11-13-2024
- KZIA 11-15-2024
- Dividend Yield
- LMFA N/A
- KZIA N/A
- EPS Growth
- LMFA N/A
- KZIA N/A
- EPS
- LMFA N/A
- KZIA N/A
- Revenue
- LMFA $12,838,084.00
- KZIA $1,655,324.00
- Revenue This Year
- LMFA N/A
- KZIA $806.89
- Revenue Next Year
- LMFA N/A
- KZIA N/A
- P/E Ratio
- LMFA N/A
- KZIA N/A
- Revenue Growth
- LMFA 27.81
- KZIA 248000.00
- 52 Week Low
- LMFA $1.84
- KZIA $1.39
- 52 Week High
- LMFA $6.11
- KZIA $15.80
- Technical
- Relative Strength Index (RSI)
- LMFA 44.22
- KZIA 20.74
- Support Level
- LMFA $1.84
- KZIA $1.42
- Resistance Level
- LMFA $2.55
- KZIA $1.89
- Average True Range (ATR)
- LMFA 0.20
- KZIA 0.24
- MACD
- LMFA 0.01
- KZIA 0.02
- Stochastic Oscillator
- LMFA 46.67
- KZIA 1.40
About LMFA LM Funding America Inc.
LM Funding America Inc is a financial services company. The company provides funding to nonprofit community associations located in the state of Florida and to nonprofit community associations in the states of Washington and Colorado. Its products include Original Product and New Neighbor Guaranty. Its original product offering consists of providing funding to Associations by purchasing their rights under delinquent accounts that are selected by the Associations arising from unpaid Association assessments. It currently has two lines of business recently commenced cryptocurrency mining business and historical specialty finance business. The Company has two operating segments: Specialty Finance and Mining Operations, which generate the majority of its revenue.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.